IMMUNOTAC Trademark

Trademark Overview

On Friday, September 7, 2018, a trademark application was filed for IMMUNOTAC with the United States Patent and Trademark Office. The USPTO has given the IMMUNOTAC trademark a serial number of 88108651. The federal status of this trademark filing is REGISTERED as of Tuesday, April 19, 2022. This trademark is owned by Silverback Therapeutics, Inc.. The IMMUNOTAC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical and therapeutics research and development services for systemically delivered, locally active immune modulatory conjugates; research and development of systemically delivered, locally active immune modulatory conjugates in the pharmaceutical, therapeutics and biotechnology fields; research and product development of systemically delivered, locally active immune modulatory conjugates in the field of human therapeutics; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases with systemically delivered, locally active immune modulatory conjugates; pharmaceutical product development of systemically delivered, locally active immune modulatory conjugates
immunotac

General Information

Serial Number88108651
Word MarkIMMUNOTAC
Filing DateFriday, September 7, 2018
Status700 - REGISTERED
Status DateTuesday, April 19, 2022
Registration Number6707689
Registration DateTuesday, April 19, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 20, 2019

Trademark Statements

Goods and ServicesPharmaceutical and therapeutics research and development services for systemically delivered, locally active immune modulatory conjugates; research and development of systemically delivered, locally active immune modulatory conjugates in the pharmaceutical, therapeutics and biotechnology fields; research and product development of systemically delivered, locally active immune modulatory conjugates in the field of human therapeutics; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases with systemically delivered, locally active immune modulatory conjugates; pharmaceutical product development of systemically delivered, locally active immune modulatory conjugates

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, September 15, 2018
Primary Code042
First Use Anywhere DateWednesday, August 11, 2021
First Use In Commerce DateWednesday, August 11, 2021

Trademark Owner History

Party NameSilverback Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109
Party NameSilverback Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109
Party NameSilverback Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events

Event DateEvent Description
Tuesday, April 19, 2022REGISTERED-PRINCIPAL REGISTER
Thursday, March 17, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, March 16, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, February 18, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 17, 2022STATEMENT OF USE PROCESSING COMPLETE
Thursday, February 10, 2022USE AMENDMENT FILED
Thursday, February 17, 2022SOU EXTENSION 4 GRANTED
Thursday, February 10, 2022SOU EXTENSION 4 FILED
Thursday, February 17, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 10, 2022TEAS EXTENSION RECEIVED
Thursday, February 10, 2022TEAS STATEMENT OF USE RECEIVED
Friday, August 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 11, 2021SOU EXTENSION 3 GRANTED
Wednesday, August 11, 2021SOU EXTENSION 3 FILED
Wednesday, August 11, 2021TEAS EXTENSION RECEIVED
Friday, February 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 10, 2021SOU EXTENSION 2 GRANTED
Wednesday, February 10, 2021SOU EXTENSION 2 FILED
Wednesday, February 10, 2021TEAS EXTENSION RECEIVED
Wednesday, August 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 3, 2020SOU EXTENSION 1 GRANTED
Monday, August 3, 2020SOU EXTENSION 1 FILED
Monday, August 3, 2020TEAS EXTENSION RECEIVED
Tuesday, February 11, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, December 29, 2019EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, September 18, 2019EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, August 20, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 20, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 31, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, July 15, 2019ASSIGNED TO LIE
Monday, July 8, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 19, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 18, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 18, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 31, 2018LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Friday, December 28, 2018LETTER OF PROTEST EVIDENCE FORWARDED
Wednesday, December 19, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 19, 2018NON-FINAL ACTION E-MAILED
Wednesday, December 19, 2018NON-FINAL ACTION WRITTEN
Tuesday, December 18, 2018ASSIGNED TO EXAMINER
Saturday, September 15, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, September 11, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

immunotac active locally immune modulatory conjugates delivered systemically research development therapeutics